Executive Lawyer, Patent Attorney & Trade Mark Attorney
BScLLB(Hons), MIP, GDLP
Masters of Industrial Property
Bachelor of Laws (with Honours)
Bachelor of Science (Molecular Genetics)
Graduate Diploma of Legal Practice
Solicitor, Registered Patent Attorney (AU, NZ)
Registered Trade Mark Attorney (AU, NZ)
Naomi is listed in IAM Patent 1000 as one of Australia’s leading patent litigators, and in IAM Strategy 300: The World’s Leading IP Strategists. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
Naomi Pearce is a strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 23 years’ experience supporting global pharma/biopharma, and a background in molecular biology/biochemistry.
Naomi’s industry focus is generic and biosimilar medicines, and she has an extensive list of generic and biosimilar clients from around the world.
Naomi’s clients value her creative, pragmatic solutions to legal/patent “problems”, and she is recognised by industry as a leader in patent strategies.
Naomi is the founding Principal of Pearce IP, which commenced in 2017. Naomi trained at leading law firm Ashurst (1997 – 2002), spent 13 years leading the biopharma IP teams of Pfizer (Hospira) and Mylan (2002 – 2015) including at VP of IP level, is a former Partner of Big Law’s K&L Gates where she Co-Chaired the K&L Gates global Pharma/Biopharma Industry Group.
Drawing from her considerable in-house experience, Naomi builds elegant market entry strategies for her clients which align with their commercial objectives, and are anchored with legal and technical excellence.
Naomi is a biosimilars IP trailblazer. Naomi’s decade of global biosimilars responsibility at Pfizer (Hospira) and at executive level at Mylan put her ahead of the curve on issues relating to the global development and launch of biosimilars. Naomi continues to lead her peers on biosimilars IP strategies and has many current active matters relating to biosimilar mAb products.
Naomi manages AU patent litigations in the Australian Courts and is a leader in multi jurisdictional litigations.
In her former life in-house, Naomi managed multiple US Hatch Waxman litigation, US BPCIA strategies, CA PMNOC proceedings, patent litigations in AU, HK, UK, DE, NE, NZ, PO, IE (among other regions), and patent oppositions before EPO, AU and NZ. Naomi’s clients use her global litigation experience to assist them manage global litigations with many moving parts, and to coordinate overseas litigations.
Naomi was the first Chair of the Legal Working Group of the Generic and Biosimilar Medicines Association of Australia (GBMA), and for many years was actively involved with various committees of the European Generics Association (EGA), the US Generic Pharmaceuticals Association (GPhA), and the US Coalition for a Competitive Pharmaceutical Market (CCPM).
Naomi is a regular international speaker on IP issues relating to small molecule and biosimilar medicines.
MIP IP Stars Patent Star 2021
IAM Patent 1000 Recommended (Silver)
IAM Strategy 300 Global Leader 2021
IAM Strategy 300 Global Leader 2020
IAM Strategy 300 World Leading IP Strategist
Women in Law Awards Finalist – Partner of the Year (SME Law)
World Intellectual Property Review Influential Women in IP 2021
World Intellectual Property Review WIPR Leader 2021
World Intellectual Property Review WIPR Leader 2020
5-Star Awards 5-Star Intellectual Property Lawyer 2021
Q1 2021 Healthcare and Life Sciences Lexology Legal Influencer
Q4 2020 Healthcare and Life Sciences Lexology Legal Influencer
Q3 2020 Healthcare and Life Sciences Lexology Legal Influencer
At Pearce IP our lawyers and attorneys have “raised the bar” for patent services. We work with life sciences clients to create and implement IP strategies with impact. From conception to post commercialisation our patent professionals provide work that is on point and on time. We help change the world, one patent at a time.